Clinical Trials News - Candlesense

D&D Pharmatech Announces Positive Phase 2 Results for DD01 in MASH with Robust Reductions in Liver Fat Accompanied by Improvements in Liver and Metabolic Health

GYEONGGI-DO, South Korea & GAITHERSBURG, Md.--(BUSINESS WIRE)--D&D Pharmatech, Inc. (D&D) (KOSDAQ: 347850), a clinical-stage biotechnology company developing breakthrough treatments for liver and m...

Symbol: 347850.KS

2 months ago

Read more businesswire

Genentech to Advance Prasinezumab Into Phase III Development for Early-Stage Parkinson’s Disease

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today its decision to proceed with Phase III development of prasinezumab...

Symbol: RHHBY

2 months ago

Read more businesswire

QIAGEN and Incyte Announce Precision Medicine Collaboration to Develop Companion Diagnostics for Patients With Mutant CALR-expressing Myeloproliferative Neoplasms (MPNs)

VENLO, Netherlands & WILMINGTON, Del.--(BUSINESS WIRE)---- $QGEN #QIAGEN--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) and Incyte (Nasdaq: INCY) today announced a new global collaboratio...

Symbol: QGEN

2 months ago

Read more businesswire

Positive Late-Breaking Data for Incyte’s First-in-Class mutCALR-targeted therapy INCA033989 in Essential Thrombocythemia Presented at EHA2025

WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Positive Late-Breaking Data for Incyte’s First-in-Class mutCALR-targeted therapy INCA033989 in Essential Thrombocythemia Presented at EHA2025

Symbol: INCY

2 months ago

Read more businesswire

Sarepta Provides Safety Update for ELEVIDYS and Initiates Steps to Strengthen Safety in Non-Ambulatory Individuals with Duchenne

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today provided a safety update regarding ELEVIDYS (delandist...

Symbol: SRPT

2 months ago

Read more businesswire

Sarepta Provides Safety Update for ELEVIDYS and Initiates Steps to Strengthen Safety in Non-Ambulatory Individuals with Duchenne

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today provided a safety update regarding ELEVIDYS (delandist...

Symbol: SRPT

2 months ago

Read more businesswire

Keymed Biosciences gibt die neuesten Ergebnisse der klinischen Studie mit CM336 bekannt, die im New England Journal of Medicine veröffentlicht wurden

CHENGDU, China, 15. Juni 2025 /PRNewswire/ -- Am 12. Juni hat Keymed Biosciences Inc. (HKEX: 02162) gab bekannt, dass Prof. Jun Shis Forschungsteam vom Institute of Hematology and Blood Diseases Ho...

Symbol: 02162.HK

2 months ago

Keymed Biosciences gibt die neuesten Ergebnisse der klinischen Studie mit CM336 bekannt, die im New England Journal of Medicine veröffentlicht wurden

CHENGDU, China, 15. Juni 2025 /PRNewswire/ -- Am 12. Juni hat Keymed Biosciences Inc. (HKEX: 02162) gab bekannt, dass Prof. Jun Shis Forschungsteam vom Institute of Hematology and Blood Diseases Ho...

Symbol: 02162.HK

2 months ago

Celldex Presents Data Demonstrating Profound Long Term Improvement in Angioedema in Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI 2025

HAMPTON, N.J., June 14, 2025 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced data demonstrating that barzolvolimab profoundly improves angioedema at 52 weeks in the ...

Symbol: CLDX

2 months ago

Jasper Therapeutics Reports Positive Data from 180mg Cohort in SPOTLIGHT Study of Briquilimab in Chronic Inducible Urticaria

11 of 12 participants (92%) enrolled in the 180mg cohort achieved a complete response

Symbol: JSPR

2 months ago